

Supplementary Information

Chalcone-9: a novel inhibitor of the JAK-STAT pathway with potent anti-cancer effects in triple-negative breast cancer cells

Song-Hee Lee^{1†}, Haeri Lee^{1,2}, Yong-Jin Kwon³, Seul-Ki Kim¹, Eun-Bi Seo^{1,2}, Jie Ohn Sohn⁴, Byung-Hak Kim⁵,
Jung-Youl Park⁶, and Sang-Kyu Ye^{1,2,4,7,8*}

¹Department of Biomedical Sciences and Pharmacology, Seoul National University College of Medicine, Seoul, 03080,
Republic of Korea

²Ischemic/Hypoxic Disease Institute, Seoul National University College of Medicine, Seoul, 03080, Republic of Korea

³Department of Cosmetic Science, Kyungsung University, Busan, 48434, Republic of Korea

⁴Wide River Institute of Immunology, Seoul National University, Hongcheon, Gangwon-do 25159, Republic of Korea

⁵Medience Co. Ltd., Chuncheon, Gangwon-do 24232, Republic of Korea

⁶Glocal University Project Group, Andong National University, Andong, Gyeongsangbuk-do 36729, Republic of Korea

⁷Biomedical Science Project (BK21PLUS), Seoul National University College of Medicine, Seoul, 03080, Republic of
Korea


⁸Neuro-Immune Information Storage Network Research Center, Seoul National University College of Medicine, Seoul,
03080, Republic of Korea

*Corresponding author: Sang-Kyu Ye, Department of Biomedical Sciences and Pharmacology, Seoul National
University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080, Republic of Korea
Tel: +82-2-740-8281; Fax: +82-2-745-7996; E-mail: sangkyu@snu.ac.kr (S.K. Ye)

† First author

A


Chalcone



Molecular Weight: 208.26


B

Chalcone-6




Molecular Weight: 358.43

Chalcone-7




Molecular Weight: 364.82

Chalcone-8



Molecular Weight: 360.40

Chalcone-9



Molecular Weight: 374.39

Fig. S1. Chemical structures of chalcone and its derivatives. (A) Structure of original chalcone (M.W. = 208.26). (B) Structures of chalcone-6 (M.W. = 358.43), chalcone-7 (M.W. = 364.82), chalcone-8 (M.W. = 360.40) and chalcone-9 (M.W. = 374.39) used in this study.




Fig. S2. Effects of chalcone-8 on cell viability in MDA-MB-231 and MDA-MB-468 cells. Cell viability was measured by CCK-8 assay in MDA-MB-231 and MDA-MB-468 cells. Cell viability is represented as % control compared with the vehicle-treated group. Data were shown as mean $\pm$ SD (n = 3).




Fig. S3. Effects of chalcone-9 on serine phosphorylation of STAT1 and STAT3 in MDA-MB-231 and MDA-MB-468 cells. Western blot analysis of STAT1 and STAT3 serine phosphorylation following treatment with 25 μ M chalcone-9 in a time-dependent manner.




Fig. S4. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 1A, depicting the labeling of pY-JAK1, JAK1, pY-JAK2, JAK2, pY-STAT1, STAT1, pY-STAT3, STAT3, and α -tubulin in vehicle or chalcone derivatives-treated MDA-MB-231 and MDA-MB-468 cells.




Fig. S5. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 2B, depicting the labeling of pY-JAK1, JAK1, pY-JAK2, JAK2, pY-JAK3, JAK3, pY-TYK2, TYK2, pY-STAT1, STAT1, pY-STAT3, pS-STAT3, STAT3, pY-STAT5, STAT5, and α-tubulin in MCF7, T47D, MDA-MB-231, and MDA-MB-468 cells.




Fig. S6. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 3A, depicting the labeling of pY-JAK1, JAK1, pY-JAK2, JAK2, pY-STAT1, STAT1, pY-STAT3, STAT3, and α -tubulin in MDA-MB-231 and MDA-MB-468 cells treated with chalcone-9 in a dose-dependent manner.




Fig. S7. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 3C, depicting the labeling of pY-JAK1, JAK1, pY-JAK2, JAK2, pY-STAT1, STAT1, pY-STAT3, STAT3, and α -tubulin in MDA-MB-231 and MDA-MB-468 cells treated with chalcone-9 in a time-dependent manner.




Fig. S8. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 3E, depicting the labeling of pY-JAK1, JAK1, pY-JAK2, JAK2, pY-STAT1, STAT1, pY-STAT3, STAT3, and GAPDH in chalcone-9, AG490, nifuroxazide, S3I-201, or STA-21-treated MDA-MB-231 and MDA-MB-468 cells.




Fig. S9. Unprocessed western blot images corresponding to the representative immunoblots shown in Fig. 6B, depicting the labeling of survivin, caspase-3, caspase-9, PARP, and GAPDH in chalcone-9-treated MDA-MB-231 cells.




Fig. S10. Unprocessed western blot images from which representative immunoblots depicting the labeling of pS-STAT1, STAT1, pS-STAT3, STAT3, and GAPDH in MDA-MB-231 and MDA-MB-468 cells are shown in Figure S3.






Fig. S11. Representative images of the wound healing assay shown in Fig. 5B (three images per experimental group). The representative images displayed in the main figure are indicated with a red box (top). Cell images of MDA-MB-231 cells treated with vehicle and chalcone-9 for 24 hours in wound healing assay with a magnification of 40X. Scale bar, 500 μ m.